FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals

被引:80
作者
Becherer, A
De Santis, M
Karanikas, G
Szabó, M
Bokemeyer, C
Dohmen, BM
Pont, J
Dudczak, R
Dittrich, C
Kletter, K
机构
[1] Univ Vienna, Ludwig Boltzmann Inst Nucl Med, Dept Nucl Med, A-1090 Vienna, Austria
[2] Kaiser Franz Josef Hosp, Dept Oncol, Ludwig Boltzmann Inst Appl Canc Res, Vienna, Austria
[3] Univ Tubingen, Dept Oncol, D-72074 Tubingen, Germany
[4] Univ Tubingen, Dept Nucl Med, D-72074 Tubingen, Germany
关键词
germ cell tumour; seminoma; residual tumour; FDG; positron emission tomography; computed tomography;
D O I
10.1016/j.ejrad.2004.07.012
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 [临床医学]; 100207 [影像医学与核医学]; 1009 [特种医学];
摘要
Aim: In advanced seminoma the management of residuals after completion of chemotherapy is controversial. Some centres routinely perform surgery for lesions >= 3 cm diameter, others recommend surgery solely if the residual fail to shrink or show even growth. This study prospectively investigates whether FDG PET can improve the prediction of viable tumour in post-chemotherapy seminoma residuals. Materials and methods: After an expansion of a previous study population, 54 patients from eight centres with metastatic seminoma and a CT-documented mass after chemotherapy were included in the study. Six patients were excluded from evaluation because of protocol violations. After PET, the patients underwent either Surgery or were followed clinically. On follow-up the lesions were considered to be non-viable when there was unequivocal shrinking, or when the lesion remained morphologically stable for at least 24 months. Any lesion growth was assumed to be malignant. PET results were compared to CT discrimination (< or >= 3 cm) of the residual masses. Results: Fifty-two PET scans were evaluable. After adequate chemotherapy, there were 74 CT-documented residual masses ranging in size from I to I I cm (median, 2.2 cm). Their dignities were confirmed histologically in 13 lesions, or by follow-up CT in 61 lesions. Four of forty-seven lesions < 3 cut and 11/27 lesions >= 3 cm were viable. PET was true positive in one lesion < 3 cm and in 11 lesions >= 3 cm, false negative in three lesions < 3 cm, and true negative in 59 lesions (43 lesions < 3 cm). No PET scan was false positive. In detecting viability the sensitivity and specificity was 73% (95% CI, 44-88), and 73% (59-83), respectively, for CT (< or >= 3 cm); and 80% (51-95), and 100% (93-100), respectively, for PET (specificity, P < 0.001). Conclusion: In post-chemotherapy seminoma residuals, a positive PET is highly predictive for the presence of viable tumour. The specificity of PET is significantly higher than that of CT when using a >= 3 cm cut-off. A negative PET scan is excellent for the exclusion of disease in lesions > 3 cm, with a somewhat higher sensitivity than CT (n.s.). PET can contribute to the management of residual seminoma lesions, especially in terms of avoiding unnecessary additional treatment for patients with lesions > 3 cm. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:284 / 288
页数:5
相关论文
共 19 条
[1]
Cremerius U, 1998, J NUCL MED, V39, P815
[2]
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma [J].
De Santis, M ;
Bokemeyer, C ;
Becherer, A ;
Stoiber, F ;
Oechsle, K ;
Kletter, K ;
Dohmen, BM ;
Dittrich, C ;
Pont, J .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (17) :3740-3744
[3]
Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma [J].
deWit, M ;
Bumann, D ;
Beyer, W ;
Herbst, K ;
Clausen, M ;
Hossfeld, DK .
ANNALS OF ONCOLOGY, 1997, 8 :57-60
[4]
Management of post-chemotherapy residual masses in advanced seminoma [J].
Fléchon, A ;
Bompas, E ;
Biron, P ;
Droz, JP .
JOURNAL OF UROLOGY, 2002, 168 (05) :1975-1979
[5]
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy [J].
Fossa, SD ;
Oliver, RTD ;
Stenning, SP ;
Horwich, A ;
Wilkinson, P ;
Read, G ;
Mead, GM ;
Roberts, JT ;
Rustin, G ;
Cullen, MH ;
Kaye, SB ;
Harland, SJ ;
Cook, P .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) :1380-1387
[6]
THERAPEUTIC GUIDELINES AND RESULTS IN ADVANCED SEMINOMA [J].
FRIEDMAN, EL ;
GARNICK, MB ;
STOMPER, PC ;
MAUCH, PM ;
HARRINGTON, DP ;
RICHIE, JP .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (10) :1325-1332
[7]
Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma [J].
Ganjoo, KN ;
Chan, RJ ;
Sharma, M ;
Einhorn, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3457-3460
[8]
Surgery for a post-chemotherapy residual mass in seminoma [J].
Herr, HW ;
Sheinfeld, J ;
Puc, HS ;
Heelan, R ;
Bajorin, DF ;
Mencel, P ;
Bosl, GJ ;
Motzer, RJ .
JOURNAL OF UROLOGY, 1997, 157 (03) :860-862
[9]
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging [J].
Jerusalem, G ;
Beguin, Y ;
Fassotte, MF ;
Najjar, F ;
Paulus, P ;
Rigo, P ;
Fillet, G .
BLOOD, 1999, 94 (02) :429-433
[10]
Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up [J].
Karapetis, CS ;
Strickland, AH ;
Yip, D ;
Steer, C ;
Harper, PG .
INTERNAL MEDICINE JOURNAL, 2003, 33 (9-10) :427-435